Learn about anaphylaxis, a severe allergic reaction, its symptoms, causes, diagnosis, treatment, prevention, and importance ...

Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

The treatment of asthma and allergic rhinitis using unique, humanized anti-IgE monoclonal antibodies with very particular binding specificities is now supported by the results of multiple phase II ...

Study reveals how a new IgE antibody therapy reactivates immune cells, offering a promising approach to fighting ovarian ...

Research has shed light on how a new type of antibody treatment reactivates patients’ immune cells to fight ovarian cancer.

An IgE antibody recognising Folate Receptor-alpha has been tested in clinical trials for ovarian cancer and preclinical studies show macrophage involvement in the anti-tumoural functions of IgE.

With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.

Epsilogen has acquired antibody developer TigaTx in a deal that collates work from the companies’ alternative antibody ...

Epsilogen completes acquisition of TigaTx to create world’s leading pan-isotype cancer antibody company: London Tuesday, April 8, 2025, 10:00 Hrs [IST] Epsilogen, the global lea ...

The combined company will clinically advance Epsilogen's MOv18 IgE antibody in ovarian cancer and TigaTx's anti-EGFR IgA antibody.